Anti-EGLN2/PHD1 antibody - 0.2mg/mL

Ref. 3D-CRB2005163

Informations sur le produit

• Nom: Anti-EGLN2/PHD1 antibody - 0.2mg/mL

Description

The human Egl nine homolog 2 (EglN2)/prolyl hydroxylase domain-containing enzyme (PHD1) is an important oxygen sensor and is responsible for the oxygen-dependent degradation and hydroxylation of hypoxia-inducible factors (HIFs). HIFs are transcription factors that respond to decreases in available oxygen in the cellular environment (hypoxia). In the presence of oxygen EglN2/PHD1 hydroxylates HIFα subunits on conserved prolines within the oxygen-dependent degradation (ODD) domain, targeting them for degradation. Under hypoxic conditions, EglNs lose their ability to hydroxylate HIFα subunits leading to HIFα stabilisation and dimerization with HIF1β (ARNT). Dimerization activates transcription of many genes linked to hypoxic adaptation, such those involved in cell proliferation, metabolism, and angiogenesis.

Due to their role in hypoxia, EglNs contribute to tumourigenesis. EglN2 mRNA levels are higher in several cancers for example in oestrogen receptor-α (ERα) positive breast cancer compared to ERα-negative breast cancer. Depleting EglN2 decreases cell proliferation in breast cancer models by diminishing cyclin D1 transcription.

Data: University of Liverpool Anti-EGLN2/PHD1 antibody (crb2005163)
Western blot analysis of whole cell extract of human osteocarcinoma (U-2 OS) and HeLa cells (20µg).
Lane 1: U-2 OS cells with GFP overexpression
Lane 2: U-2 OS cells with GFP-PHD1 overexpression
Lane 3: HeLa cells transfected with control siRNA.
Lane 4: HeLa cells transfected with siPHD1.
Western blot image provided courtesy of Prof. Sonia Rocha.

• Marque: Biosynth